POZ - News : GSK Drops Price on 14 HIV Drugs
Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » News » February 2008

Web Exclusives

Evaluating the Costs of Earlier HIV Treatment

HIV Prevention Gets “Fergalicious”

Changing the HIV Treatment Paradigm

» More

Most Talked About

Magic Johnson Accused of Faking HIV (41)

The POZ/DDF Ratio (blog) (30)

Guidelines Prediction: Start Treatment Earlier (blog) (16)

HIV-Positive People Living Longer Than Ever Before (14)

Bone Marrow Transplant: Potential AIDS Cure? (8)

Obama Campaign Set to Boost Domestic HIV/AIDS Funding (8)

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

10 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

February 20, 2008

GSK Drops Price on 14 HIV Drugs

On February 19, pharmaceutical company GlaxoSmithKline, one of the world’s largest producers of HIV medications, announced that it is cutting the prices of 14 antiretroviral drugs sold in developing countries, the Wall Street Journal reports (blogs.wsj.com, 2/19). According to the Journal, this is the company’s fifth price rollback since 1997.

Prices of the 14 drugs will drop by an average of 21 percent, according to GlaxoSmithKline, due to the availability of cheaper ingredients and improvements in manufacturing.  

The biggest price cut will be in a drug called Ziagen, the liquid form of which is recommended by the World Health Organization for use in children. The price of Ziagen will drop by 40 percent to cost $15.08 per pack, or 50 cents a day. The company’s most expensive HIV drug, Lexiva, will drop in price by 20 percent, to a new cost of $3.35 a day.


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

  comments 1 - 4 (of 4 total)    

mb, , 2008-02-26 08:56:15
Others should do the same but also Drop the Prices here in the U.S.A. What's good for some Geese is good for the entire Gander

John, Houston, 2008-02-21 20:35:17
Why do they not salso drop the prices in the US? How about dropping the price on all of their HIV medications?

Mark, Maryville, 2008-02-21 09:15:46
I wonder why GSK can not drop the prices here in the USA? I guess that they are under the assumption that everyone in the USA can afford OVER PRICED Anti-virals.

Alfredo, Baltimore, 2008-02-20 22:33:49
GSK should be commended for lowering their prices. Obviously, this will impact lives in developing countries in positive way. Hopefully, other pharmaceutical companies will take GSK's lead. Kudos to GSK! I reccomend people write GSK execs and thank them for this humanitarian measure.

comments 1 - 4 (of 4 total)    


[Go to top]


Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Would legalizing prostitution reduce the spread of HIV?
Yes
No
I don't know.

Monthly Poll
Question: Do you believe that prisoners receive adequate health care?
Yes
No
I don't know.

Surveys
Tell us about your overall health habits.

Tell us when and to whom you disclose your status.

more surveys
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy